SCHEMBL4469820

SCHEMBL4469820

COC(=O)c1ccc2c(c1)COc1cc(CCN)ccc1-2

nearest known ligand 0.51

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 19/20 0.51
LOXL2 Q9Y4K0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL205863 0.84 ROCK2 (0.52) ROCK2
SCHEMBL38657847 0.82 ROCK2 (0.52) ROCK2
SCHEMBL4459885 0.81 ROCK2 (0.48) ROCK2
SCHEMBL24502972 0.79 KDM4E (0.52) ROCK2
SCHEMBL205164 0.79 ROCK2 (0.52) ROCK2
SCHEMBL751196 0.79 KDM4E (0.57) ROCK2
SCHEMBL20788479 0.77 ROCK2 (0.55) ROCK2
SCHEMBL30529024 0.77 ROCK2 (0.55) ROCK2
SCHEMBL24503081 0.77 KDM4E (0.52) ROCK2
SCHEMBL205835 0.75 ROCK2 (0.48) ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629366-B2 Aminoalcohol derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2009-12-08 US disclosed
US-20060100252-A1 Aminoalcohol derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2006-05-11 US disclosed
US-7037938-B2 Aminoalcohol derivatives ASTELLAS PHARMA INC. (JP) 2006-05-02 US disclosed
US-20040006143-A1 For therapy of urinary incontinence FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100252-A1 Aminoalcohol derivatives H1-0, CHRM2, CHRM1 ROCK2 3982/4885LOXL2 1488/4885
US-20040006143-A1 For therapy of urinary incontinence H1-0, HRH2, H1-2 ROCK2 2861/4885LOXL2 1585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.